Immunotherapy in GU Cancers

Publication
Article
Special ReportsImmunotherapy (Issue 5)
Volume 5
Issue 1

Mark A. Rubin, MD, director, Institute for Precision Medicine, Weill Cornell Medical College, discusses immunotherapy in the field of genitourinary cancers.

Mark A. Rubin, MD, director, Institute for Precision Medicine, Weill Cornell Medical College, discusses immunotherapy in the field of genitourinary cancers.

<<<

View the entire Special Report on Immunotherapy

Articles in this issue
The Rationale for Immunotherapy in NSCLC
The Rationale for Immunotherapy in NSCLC
Maximizing Immunotherapy Approaches in Hard-to-Treat Cancers
Maximizing Immunotherapy Approaches in Hard-to-Treat Cancers
Rich Immunotherapy Pipeline for Melanoma Under Way
Rich Immunotherapy Pipeline for Melanoma Under Way
Tumor Antigens and Their Role in Immune Response in Melanoma
Tumor Antigens and Their Role in Immune Response in Melanoma
Major Programs Under Way in Immuno-Oncology
Major Programs Under Way in Immuno-Oncology
PD-1 Inhibitors for Melanoma
PD-1 Inhibitors for Melanoma
Immunotherapy in GU Cancers
Immunotherapy in GU Cancers
Immune-Related AEs and Their Management: Q & A With Michael A. Postow, MD
Immune-Related AEs and Their Management: Q & A With Michael A. Postow, MD

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
1 expert in this video
1 expert in this video
Related Content
Dr Hankins Investigates Erectile Dysfunction Risk After Prostate Cancer Radiation

Dr Hankins Investigates Erectile Dysfunction Risk After Prostate Cancer Radiation

Jordyn Sava
July 5th 2025
Article

A new study reveals that rectal spacers during prostate cancer radiation therapy significantly reduce long-term erectile dysfunction rates, enhancing patient outcomes.

Read More

Transforming Prostate Cancer Care Through Personalized Medicine

Transforming Prostate Cancer Care Through Personalized Medicine

Jordyn Sava;Adam Weiner, MD
July 1st 2024
Podcast

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Listen

FDA Grants Breakthrough Designation for Novel Bladder Cancer Diagnostic

FDA Grants Breakthrough Designation for Novel Bladder Cancer Diagnostic

Sabrina Serani
July 2nd 2025
Article

The FDA designates the TOBY Test as a breakthrough device, revolutionizing bladder cancer detection with a non-invasive, AI-driven urine test.

Read More

Dizman’s Global Pursuit to Cancer Research and Understanding

Dizman’s Global Pursuit to Cancer Research and Understanding

Jordyn Sava;Nazli Dizman, MD
April 1st 2024
Podcast

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Listen

TROP-2 Inhibitors Are Explored in Breast Cancer

TROP-2 Inhibitors Are Explored in Breast Cancer

Tony Berberabe, MPH
June 28th 2025
Article

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert insights and groundbreaking research.

Read More

Bladder-Sparing Approaches Gaining Ground in NMIBC

Bladder-Sparing Approaches Gaining Ground in NMIBC

Tony Berberabe, MPH
June 27th 2025
Article

Innovative treatments for non–muscle-invasive bladder cancer emerge, focusing on bladder preservation and improved outcomes with novel therapies and active surveillance strategies.

Read More